33313-64-3Relevant academic research and scientific papers
Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacy
Pettersson, Martin,Johnson, Douglas S.,Rankic, Danica A.,Kauffman, Gregory W.,Am Ende, Christopher W.,Butler, Todd W.,Boscoe, Brian,Evrard, Edelweiss,Helal, Christopher J.,Humphrey, John M.,Stepan, Antonia F.,Stiff, Cory M.,Yang, Eddie,Xie, Longfei,Bales, Kelly R.,Hajos-Korcsok, Eva,Jenkinson, Stephen,Pettersen, Betty,Pustilnik, Leslie R.,Ramirez, David S.,Steyn, Stefanus J.,Wood, Kathleen M.,Verhoest, Patrick R.
, p. 730 - 743 (2017)
Herein we describe the discovery of a novel series of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators for the treatment of Alzheimer's disease (AD). Using ligand-based design tactics such as conformational analysis and molecul
CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS
-
Page/Page column 102; 104; 114, (2015/12/30)
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b/su
16-Substituted polyunsaturated hexadecanoic fatty acids
-
, (2008/06/13)
Sixteen carbon atom carboxylic acids having 16-phenoxy or 16-phenylthio substituents, and 0, 1, or 4 triple bonds, methods of preparing them, and pharmaceutical preparations containing them. These compounds are useful as lipoxygenase inhibitors.
